Repligen (NASDAQ:RGEN) Upgraded by Wolfe Research to Outperform Rating

Wolfe Research upgraded shares of Repligen (NASDAQ:RGEN) from a peer perform rating to an outperform rating in a report issued on Tuesday, MarketBeat.com reports. Wolfe Research currently has $160.00 price target on the biotechnology company’s stock.

Other research analysts also recently issued reports about the company. JPMorgan Chase & Co. boosted their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, February 21st. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Monday. Canaccord Genuity Group dropped their price target on shares of Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research report on Wednesday, April 16th. Royal Bank of Canada upped their price objective on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research report on Friday, February 21st. Finally, Evercore ISI started coverage on Repligen in a research report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $173.25.

Repligen Stock Down 0.6 %

NASDAQ:RGEN opened at $137.20 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company’s fifty day moving average price is $138.22 and its 200-day moving average price is $145.83. Repligen has a 1-year low of $102.97 and a 1-year high of $182.52. The firm has a market capitalization of $7.70 billion, a P/E ratio of -269.02, a PEG ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period last year, the firm earned $0.28 EPS. As a group, equities research analysts anticipate that Repligen will post 1.72 EPS for the current year.

Insider Transactions at Repligen

In other news, Director Margaret Pax bought 250 shares of the business’s stock in a transaction on Monday, March 17th. The shares were bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

A number of institutional investors have recently modified their holdings of the company. UMB Bank n.a. grew its position in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 110 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of Repligen in the fourth quarter valued at approximately $216,000. Van ECK Associates Corp grew its holdings in shares of Repligen by 7.8% in the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock valued at $6,078,000 after purchasing an additional 3,066 shares in the last quarter. Stephens Investment Management Group LLC increased its stake in Repligen by 7.4% during the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock worth $77,267,000 after buying an additional 37,057 shares during the period. Finally, Artemis Investment Management LLP lifted its holdings in Repligen by 18.4% during the 4th quarter. Artemis Investment Management LLP now owns 153,832 shares of the biotechnology company’s stock worth $22,143,000 after buying an additional 23,905 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.